[{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Not Applicable"},{"orgOrder":0,"company":"Pacific Pediatric Neuro-Oncology Consortium","sponsor":"Kazia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"ONC-201","moa":"Dopamine","graph1":"Oncology","graph2":"Undisclosed","graph3":"Pacific Pediatric Neuro-Oncology Consortium","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pacific Pediatric Neuro-Oncology Consortium \/ Kazia Therapeutics"},{"orgOrder":0,"company":"Oncoceutics Inc","sponsor":"Chimerix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Oncoceutics Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Oncoceutics Inc \/ Chimerix","highestDevelopmentStatusID":"8","companyTruncated":"Oncoceutics Inc \/ Chimerix"},{"orgOrder":0,"company":"Kazia Therapeutics","sponsor":"Pacific Pediatric Neuro-Oncology Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ONC201","moa":"DRD2","graph1":"Oncology","graph2":"Phase II","graph3":"Kazia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium","highestDevelopmentStatusID":"8","companyTruncated":"Kazia Therapeutics \/ Pacific Pediatric Neuro-Oncology Consortium"},{"orgOrder":0,"company":"Chimerix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONC201","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chimerix \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chimerix \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for ONC201

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.

                          Brand Name : ONC201

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 08, 2022

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : At the outset, all patients will be treated with ONC201, combined with either paxalisib or panobinostat. The study employs an adaptive design, in which different arms will be opened and closed based on emerging preclinical and clinical data.

                          Brand Name : ONC201

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 11, 2021

                          Lead Product(s) : ONC201,Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Pacific Pediatric Neuro-Oncology Consortium

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation.

                          Brand Name : ONC201

                          Molecule Type : Small molecule

                          Upfront Cash : $39.0 million

                          January 08, 2021

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Chimerix

                          Deal Size : $78.0 million

                          Deal Type : Acquisition

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Kazia Therapeutics has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium to launch a clinical trial of multiple therapies, including Kazia's investigational, paxalisib, in diffuse midline gliomas including diffuse intrinsic...

                          Brand Name : ONC-201

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 10, 2020

                          Lead Product(s) : ONC201,Paxalisib

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Kazia Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics to receive a Rare Pediatric Disease Priority Review Voucher.

                          Brand Name : ONC201

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 21, 2020

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The data presented at ASCO 2020 highlights the potential of ONC201 to address the substantial need for patients with H3 K27M-mutant glioma.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 28, 2020

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Clinical trial provides Japanese patients with high-grade glioma immediate access to ONC201. Data from this study will be an important part of working toward a Japanese market approval for ONC201.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 01, 2020

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 26, 2020

                          Lead Product(s) : ONC201

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank